Investors are paying premium for the stock despite its limited growth. However, maintaining these prices may be challenging as recent earnings trends could depress the shares. The company's three-year earnings trends aren't affecting its P/E as much as anticipated, considering they look worse than current market expectations.
Shaanxi Panlong Pharmaceutical Stock Forum
No comment yet